Lipodystrophy Fat Loss / Fat Accumulation / Wasting / Cosmetic Procedures / Growth Hormone / Buffalo Hump
Successful Treatment of Facial Lipoatrophy with a New Formulation of Hyaluronic Acid (Restylane SubQ) 10-20-2009 Switching from Lopinavir/ritonavir (Kaletra) to Boosted Atazanavir (Reyataz) Reduces Visceral Fat and Improves Glucose Metabolism 7-10-2009 4-Year Study Finds Polyacrylamine Hydrogel (Aquamid) Facial Filler Is a Safe and Satisfactory Treatment for Lipoatrophy 5/05/09 Durable Effects of Polylactic Acid for Facial Lipoatrophy in People with HIV 4/10/09 Inflammatory Blood Vessel Activation Is Enhanced in HIV Positive People Independent of Antiretroviral Therapy and Lipoatrophy 12/05/2008 Strength Training Improves Insulin Sensitivity and Reduces Body Fat in HIV Positive Patients with Lipodystrophy 10/17/08 Long-term Safety and Effectiveness of Growth Hormone Releasing Factor Tesamorelin for Lipodystrophy 9/15/08 Genetic Factors May Influence Fat Loss and Accumulation in People with HIV 9/15/08 Switching from Other Ritonavir-boosted Protease Inhibitors to Boosted Atazanavir (Reyataz) Did Not Improve Body Fat Accumulation: REAL Study 8/19/2008 Growth Hormone Improves Lipodystrophy, but Has Detrimental Effect on Blood Glucose 8/08/08 Abdominal Fat Accumulation, Elevated ALT, and Liver Steatosis in HIV Positive Individuals 6/24/08 Phase 3 Study Shows Growth Hormone Releasing Factor Tesamorelin Reduces Excess Visceral Fat in HIV patients 6/20/08 Long-term Fat Loss among Treatment-naive Patients Starting Combination Therapy Containing Stavudine (Zerit), Zidovudine (Retrovir), or Abacavir (Ziagen) 5/30/08
Body Fat and Blood Lipid Levels in Men and Women with HIV 5/16/08 Genetic Variation Predicts Higher Risk of Lipoatrophy in Patients on HAART 5/02/08
